Inhibition of the transcription factor ATF4 also suppresses autophagy-dependent AML cell growth and reverses overall mouse survival [93], suggesting that targeting the ATF4-dependent autophagy pathway has therapeutic potential for patients with AML and FLT3 mutations. This evidence concerns the gene ATF4 and acute myeloid leukemia.